Upregulation of SPHK1 has been reported to have the potential to act as a prognostic biomarker in many human cancers, including oral squamous cell carcinoma [19], prostate cancer [20], gastric cancer [21], astrocytoma [22], and breast cancer [23, 24]. This evidence concerns the gene SPHK1 and breast cancer.